1
|
Inwards DJ, Fishkin PA, LaPlant BR, Drake MT, Kurtin PJ, Nikcevich DA, Wender DB, Lair BS, Witzig TE. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol 2019; 30:346. [PMID: 29390098 PMCID: PMC6386023 DOI: 10.1093/annonc/mdx814] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Inwards DJ, Fishkin PA, LaPlant BR, Drake MT, Kurtin PJ, Nikcevich DA, Wender DB, Lair BS, Witzig TE. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol 2014; 25:2020-2024. [PMID: 25057177 DOI: 10.1093/annonc/mdu273] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We conducted this trial to determine the maximum tolerated dose (MTD) of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma. PATIENTS AND METHODS A standard phase I cohort of three study design was utilized. The fixed doses of rituximab and cladribine were 375 mg/m(2) i.v. day 1 and 5 mg/m(2)/day i.v. days 1-5 of a 28-day cycle, respectively. There were five planned temsirolimus i.v. dose levels: 15 mg day 1; 25 mg day 1; 25 mg days 1 and 15; 25 mg days 1, 8 and 15; and 25 mg days 1, 8, 15, and 22. RESULTS Seventeen patients were treated: three each at levels 1-4 and five at dose level 5. The median age was 75 years (52-86 years). Mantle Cell International Prognostic Index (MIPI) scores were low in 6% (1), intermediate in 59% (10), and high in 35% (6) of patients. Five patients were treated at level 5 without dose limiting toxicity. Hematologic toxicity was frequent: grade 3 anemia in 12%, grade 3 thrombocytopenia in 41%, grade 4 thrombocytopenia in 24%, grade 3 neutropenia in 6%, and grade 4 neutropenia in 18% of patients. The overall response rate (ORR) was 94% with 53% complete response and 41% partial response. The median progression-free survival was 18.7 months. CONCLUSIONS Temsirolimus 25 mg i.v. weekly may be safely added to rituximab and cladribine at 375 mg/m(2) i.v. day 1 and 5 mg/m(2)/day i.v. days 1-5 of a 28-day cycle, respectively. This regimen had promising preliminary activity in an elderly cohort of patients with mantle cell lymphoma. CLINICALTRIALSGOV IDENTIFIER NCT00787969.
Collapse
Affiliation(s)
- D J Inwards
- Division of Hematology, Mayo Clinic, Rochester.
| | - P A Fishkin
- Illinois Oncology Research Association, Peoria
| | - B R LaPlant
- Division of Endocrinology, Mayo Clinic, Rochester
| | - M T Drake
- Division of Endocrinology, Mayo Clinic, Rochester
| | - P J Kurtin
- Division of Hematopathology, Mayo Clinic, Rochester
| | - D A Nikcevich
- Department of Medical Oncology, Essentia Duluth Clinic, Duluth
| | - D B Wender
- Department of Oncology, Siouxland Hematology-Oncology Associates, Sioux City
| | - B S Lair
- Department of Oncology, Iowa Oncology Research Association, Des Moines, USA
| | - T E Witzig
- Division of Hematology, Mayo Clinic, Rochester
| |
Collapse
|
3
|
Ansell SM, Tang H, Kurtin PJ, Koenig PA, Nowakowski GS, Nikcevich DA, Nelson GD, Yang Z, Grote DM, Ziesmer SC, Silberstein PT, Erlichman C, Witzig TE. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma. Leukemia 2011; 26:1046-52. [PMID: 22015775 PMCID: PMC3266999 DOI: 10.1038/leu.2011.297] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Follicular lymphoma exhibits intratumoral infiltration by non-malignant T lymphocytes inluding CD4+CD25+ regulatory T (Treg) cells. We combined denileukin diftitox with rituximab in previously untreated, advanced-stage follicular lymphoma patients anticipating that denileukin diftitox would deplete CD25+ Treg cells while rituximab would deplete malignant B-cells. Patients received rituximab 375 mg/m2 weekly for 4 weeks and denileukin diftitox 18 mcg/kg/day for 5 days every 3 weeks for 4 cycles; neither agent was given as maintenance therapy. Between August 2008 and March 2010, 24 patients were enrolled. One patient died before treatment was given and was not included in the analysis. Eleven of 23 patients (48%; 95% CI: 27–69%) responded; 2 (9%) had complete responses and 9 (39%) had partial responses. The progression-free rate at 2 years was 55% (95%CI: 37–82%). Thirteen patients (57%) experienced grade ≥3 adverse events and 1 patient (4%) died. In correlative studies, soluble CD25 and the number of CD25+ T-cells decreased after treatment, however there was a compensatory increase in IL-15 and IP-10. We conclude that while the addition of denileukin diftitox to rituximab decreased the number of CD25+ T-cells, denileukin diftitox contributed to the toxicity of the combination without an improvement in response rate or time to progression.
Collapse
Affiliation(s)
- S M Ansell
- Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Windschilt HE, Zhao X, Loprinzi CL. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4025 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. We recently demonstrated the protective effect of CaMg against oxaliplatin-induced sNT as assessed by NCI-CTC (Nikcevich ASCO 2008). It is unclear, though, if CaMg reduced acute and/or chronic, cumulative sNT. Methods: 104 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a double-blinded manner. NCI-CTC, an oxaliplatin-specific sNT scale and patient-reported outcome (PRO) questionnaires were used to differentially assess the effect of CaMg on acute (effect on sNT on days 1–4 after oxaliplatin) and chronic sNT (area between curves over whole course of therapy). Results: A total of 102 pts (50 CaMg, 52 PL; 96 mFOLFOX6, 6 FOLFOX4) were available for analysis. Apart from a strong reduction in muscle cramps with CaMg (p=0.002), no difference was found between CaMg and PL in PRO with regard to items reflecting acute sNT (e.g. sensitivity to cold, swallowing of cold liquids, throat discomfort) on days 1–4 after oxaliplatin of any treatment cycle. In contrast, CaMg was able to significantly reduce cumulative sNT in form of numbness in fingers (p=0.02), impaired ability to button shirts (p=0.05), tingling in fingers (p=0.06), and muscle cramps over the course of therapy (p=0.01). Conclusions: In our phase III, placebo-controlled trial, CaMg was able to significantly reduce chronic, cumulative sNT related to oxaliplatin as evaluated by specific PRO questionnaires. No effect was noted on phenomena associated with acute sNT. CaMg can be recommended as neuroprotectant against oxaliplatin-related chronic sNT, oxaliplatin's dose-limiting toxicity. [Table: see text]
Collapse
Affiliation(s)
- A. Grothey
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - D. A. Nikcevich
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - J. A. Sloan
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - J. W. Kugler
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - P. T. Silberstein
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - T. Dentchev
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - D. B. Wender
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - H. E. Windschilt
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - X. Zhao
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - C. L. Loprinzi
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| |
Collapse
|
5
|
Micallef IN, Maurer MJ, Nikcevich DA, Cannon MW, Schaefer EW, Moore DF, Kurtin P, Witzig TE. Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8508] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8508 Background: A prior pilot study of epratuzumab (Immunomedics) and rituximab in combination with CHOP chemotherapy (ER-CHOP) in untreated patients with diffuse large B-cell lymphoma demonstrated feasibility and safety. This multicenter NCCTG phase II study was carried out to assess efficacy. Methods: Patients received immunochemotherapy on the following schedule: epratuzumab 360 mg/m2, rituximab 375 mg/m2, and standard dose CHOP every 3 weeks for 6 cycles. Weekly blood counts were obtained to monitor hematological toxicity. Primary endpoint was 12 month event free survival (EFS12). Secondary endpoints were response rate, progression free survival, functional CR (PET negative) and toxicity. Results: 107 patients were accrued from Feb 2006 to Aug 2007. 29 patients were ineligible resulting in 78 eligible patients. Baseline patient characteristics for the eligible patients included median age 61 (range 21–82); 59% were male. 81% had advanced stage; IPI was 0–1 in 17 pts (22%), 2 in 22 pts (28%), 3 in 29 pts (37%) and 4–5 in 10 pts (13%). Based on the revised IPI (R-IPI) 50% were poor/high risk (IPI 3–5). 71% had an elevated LDH. Performance score was 0–1 in 69 pts and 2–3 in 9 pts. The ORR was 95% (CR/CRu: 73%). For the low risk IPI (0–2), ORR was 95% (CR/CRu: 74%) and for the high risk IPI (3–5), ORR was 95% (CR/CRu: 72%). The EFS at 12 months was 80%. The 12 month progression free survival (PFS12) and overall survival (OS12) is 82% and 88% respectively. EFS12, PFS12 and OS12 by IPI risk category is shown ( Table ). Conclusions: ER-CHOP every 21 days is feasible and safe. The ORR, EFS and PFS compare favorably to studies using R-CHOP especially in the high-intermediate and high risk IPI subgroups. A randomized phase III trial of R-CHOP vs ER-CHOP is needed to prove that dual antibody targeting in combination with CHOP is better. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. N. Micallef
- Mayo Clinic, Rochester, MN; St. Mary's Duluth Clinic, Duluth, MN; Cancer Center of Kansas PA, Wichita, KS
| | - M. J. Maurer
- Mayo Clinic, Rochester, MN; St. Mary's Duluth Clinic, Duluth, MN; Cancer Center of Kansas PA, Wichita, KS
| | - D. A. Nikcevich
- Mayo Clinic, Rochester, MN; St. Mary's Duluth Clinic, Duluth, MN; Cancer Center of Kansas PA, Wichita, KS
| | - M. W. Cannon
- Mayo Clinic, Rochester, MN; St. Mary's Duluth Clinic, Duluth, MN; Cancer Center of Kansas PA, Wichita, KS
| | - E. W. Schaefer
- Mayo Clinic, Rochester, MN; St. Mary's Duluth Clinic, Duluth, MN; Cancer Center of Kansas PA, Wichita, KS
| | - D. F. Moore
- Mayo Clinic, Rochester, MN; St. Mary's Duluth Clinic, Duluth, MN; Cancer Center of Kansas PA, Wichita, KS
| | - P. Kurtin
- Mayo Clinic, Rochester, MN; St. Mary's Duluth Clinic, Duluth, MN; Cancer Center of Kansas PA, Wichita, KS
| | - T. E. Witzig
- Mayo Clinic, Rochester, MN; St. Mary's Duluth Clinic, Duluth, MN; Cancer Center of Kansas PA, Wichita, KS
| |
Collapse
|
6
|
Markovic SN, Suman VJ, Kottschade LA, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ. A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9055 Background: There is increasing evidence that paclitaxel and carboplatin are clinically active in the treatment of metastatic melanoma (MM). Nab-P is an albumin-bound paclitaxel with ability to bind SPARC (secreted protein acid rich in cysteine), that is overexpressed in MM and associated with poor prognosis. This study explores the clinical activity of the combination of nab-P and C in patients (pts) with stage IV melanoma and SPARC correlatives. Methods: A parallel phase II trial was conducted in pts with unresectable stage IV melanoma, who were either chemotherapy naïve (CN) or were previously treated (PT). A treatment regimen consisting of nab-P (100 mg/m2) and C (AUC 2) was administered on days 1, 8, and 15 of a 28 day cycle. The primary aim of this study was to assess whether tumor response rate (CR + PR by RECIST) was ≤15% vs ≥35% in the CN group and ≤5% vs ≥ 20% in the PT cohort. Major eligibility criteria: ≥18 years of age, ECOG PS ≤2, adequate organ function, platinum or taxane naive, peripheral neuropathy < grade 2, and no untreated brain metastasis; no pregnant and/or nursing women. Tumor tissue was tested for SPARC and level 3 immunohistochemical staining was considered positive. Results: 76 pts (41-CN and 35 PT) enrolled from 11/2006 - 7/2007, 3 pts (2-CN, 1-PT) cancelled prior to starting treatment. The median number of cycles administered was 4 (range 1–18-CN and 1–10-PT). There were 11 (28.2%) confirmed responses (1 CR and 10 PRs) in the CN cohort (90% CI: 16.7–42.3%) and 3 (8.8%) confirmed responses (3 PRs) in the PT cohort (90% CI: 2.5–21.3%). Median PFS was 4.5 months (CN) and 4.1 months (PT). Median OS was 11.1 months (CN) and 10.9 months (PT).The most common severe toxicities in both groups (CTCAE ≥ grade 3) included neutropenia, thrombocytopenia, neuro-sensory, fatigue, nausea, and vomiting. PFS was not affected by SPARC positivity; however, based on limited data there is some evidence that OS may be longer with tumoral SPARC positivity (10.0 vs 12.8 mo; SPARC negative vs SPARC positive). Conclusions: The weekly combination of nab-P and C appears to be well tolerated with promising clinical activity as front line or salvage therapy in pts with MM. SPARC positivity may be associated with improved OS. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. N. Markovic
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - V. J. Suman
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - L. A. Kottschade
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - T. Amatruda
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - R. R. McWilliams
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - D. A. Nikcevich
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - R. F. Morton
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - T. R. Fitch
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| | - A. J. Jaslowski
- Mayo Clinic, Rochester, MN; Metro Minnesota Community Clinical Oncology Program, St. Louis Park, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Duluth Community Clinical Oncology Program, Duluth, MN; Iowa Oncology Research Association CCOP, Des Moines, IA; Mayo Clinic Scottsdale, Scottsdale, AZ; St. Vincent Regional Cancer Center CCOP, Green Bay, WI; Abraxis Bioscience LLC
| |
Collapse
|
7
|
Apsey H, Roy V, Pockaj B, Northfelt D, Sticca R, Nikcevich DA, Mattar B, Fitch T, Perez EA. Surgical practice patterns following NCCTG N0338 “Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer.”. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
623 Background: Neoadjuvant therapy plays an important role in breast cancer treatment. Unlike patients who undergo surgery followed by adjuvant therapy,there are no established guidelines for surgical management following neoadjuvant therapy. Methods: Surgical practice patterns from 50 patients in N0338 “Phase II trial of Docetaxel and Carboplatin administered every two weeks as induction therapy for Stage II and Stage III breast cancer” were reviewed. The protocol did not mandate surgical therapy leaving the decision to the treating surgeon and patient. Results: 66% of patients underwent mastectomy (M) and 33% underwent breast conservation therapy (BCT). Three (9%) had immediate reconstruction. Eight (24%) underwent contralateral prophylactic M. Residual tumor size did not always impact primary surgical therapy. In the M group 4 (12%) had no residual disease, 15 (45%) < 2cm and 14 (42%) > 2cm; whereas, in the BCT group 1 (6%) had no residual disease, 12 (70%) < 2cm and 4 (24%) > 2cm. Axillary lymph node (ALN) staging varied tremendously. Three (6%) patients presented with palpable lymphadenopathy and proceeded to complete axillary lymph node dissection (ALND) after chemotherapy (CT). Fine needle aspiration (8) or core needle biopsy (7) of the axilla was performed in 15 (30%) patients before CT; 1 was negative and went on to have sentinel lymph node biopsy (SLNB) after CT; 14 (94%) were positive with 13 (86%) going on to ALND and 1 SLNB after CT. Five (10%) underwent SLNB prior to CT. One (20%) was positive and went on to have ALND after CT; 4 (8%) were negative and had no further ALN staging. A total of 19 (39%) had SLNB after neoadjuvant therapy; 13 (68%) were positive and underwent ALND; 1 SLNB failed; 2 of 5 that were negative underwent ALND with 1 having a positive lymph node. Ten (20%) underwent ALND with no pre-operative staging with 8 being positive for ALN metastases. Conclusions: Review of study data from multiple institutions revealed no consistent criteria in selection of surgical intervention for the breast tumor or ALN staging. There remains a need for further research in this area to establish standard practice guidelines. Support from NIH, sanofi-aventis, Amgen, Breast Cancer Research Foundation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Apsey
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| | - V. Roy
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| | - B. Pockaj
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| | - D. Northfelt
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| | - R. Sticca
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| | - D. A. Nikcevich
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| | - B. Mattar
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| | - T. Fitch
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| | - E. A. Perez
- Mayo Clinic Arizona, Phoenix, AZ; Mayo Clinic Minnesota, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; University of North Dakota, Grand Forks, ND; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic Florida, Jacksonville, FL
| |
Collapse
|
8
|
Johnson BS, Dueck AC, Dakhil SR, Stella PJ, Nikcevich DA, Franco SX, Wender DB, Schaefer PL, Colon-Otero G, Diekmann BB, Perez EA. Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: initial safety data from the Mayo Clinic cancer research consortium trial RC0639. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2109
Background: Despite the impressive results of the recently released trastuzumab adjuvant therapy trials, 15% of patients with HER2 overexpressing or amplified breast cancer developed tumor relapse at 4 years. Lapatinib is a small molecule reversible TKI that inhibits both ErbB1 and ErbB2. The current study was developed to assess the cardiac safety and feasibility of adding lapatinib to paclitaxel and trastuzumab following as part of adjuvant therapy.
 Methods: A single-arm phase II study of doxorubicin (A, 60 mg/m2 day 1) and cyclophosphamide (C, 600 mg/m2 day 1) [q2w or q3w for 4 cycles]; followed by paclitaxel (P, 80 mg/m2 days 1, 8, 15), trastuzumab (T, 4 mg/kg loading dose then 2 mg/kg days 1, 8, 15), and lapatinib (L, 1000 mg days 1-21) [12 weeks]; followed by T (6 mg/kg day 1) and L (1000 mg days 1-21) [40 weeks] was conducted. The primary endpoint was the incidence of congestive heart failure. The current unplanned safety analysis was undertaken due to the observance of a high rate of G3/4 diarrhea.
 Results: From April 2007 to June 2008, 98 pts were enrolled and initiated study treatment. Median age was 51 (range 32-72). Among 83 pts with adverse event (AE) data available, 50 (60%) pts have experienced a G3/4 non-hematologic AE. During post-AC treatment, among 53 pts with AE data available, 31 (58.5%) patients have experienced a G3/4 non-hematologic AE with 24 (45%) patients reporting G3/4 diarrhea. Median cycle of onset of G3/4 diarrhea was cycle 5 (first cycle of PTL) with 16 (64%) cases first reported during cycle 5 and 5 (20%) cases first reported during cycle 6. Among 57, 46, 38, and 32 pts receiving treatment with PTL during cycles 5-8, 65%, 57%, 61%, and 72% of patients received the full L dose, respectively. 31 patients have ended active treatment with 10 due to patient refusal and 8 due to adverse events.
 Conclusions: Preliminary data suggest that L given concurrently with P and T at a dose of 1000 mg per day induces an unacceptable rate of moderate to severe diarrhea. Careful monitoring of diarrhea as well as L dose reduction and initiation of loperamide at first occurrence of diarrhea are recommended. The dose of L when given concurrently with P and T has been amended to 750 mg per day in the current study and safety data for the 1000 mg and 750 mg per day cohorts will be presented. Implications for the ongoing ALTTO study will also be presented.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2109.
Collapse
Affiliation(s)
| | | | | | - PJ Stella
- 4 Michigan Consortium, Ann Arbor, MI
| | | | | | - DB Wender
- 6 Siouxland Hem-Onc Assoc, Sioux City, IA
| | | | | | | | | |
Collapse
|
9
|
Kottschade LA, Suman VJ, Amatruda T, McWilliams RR, Dakhil SR, Nikcevich DA, Morton RF, Fitch TR, Jaslowski AJ, Markovic SN. A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Jett JR, Bernath AM, Foster NR, Molina JR, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM, Fitch TR, Adjei AA. Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8066] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Nikcevich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Windschitl HE, Loprinzi CL. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4009] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Roy V, Pockaj BA, Northfelt DW, Allred JB, Liu H, Nikcevich DA, Mattar BI, Perez EA. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.563] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore DF, Kurtin P, Witzig TE. A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8500] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, Michalak JC, Salim M, Nikcevich DA, Dakhil SR, Fitch TR. Salvage chemotherapy with rituximab DHAP (RDHAP) for relapsed non-hodgkin lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7574 Background: Patients (pts) with relapsed aggressive NHL are usually treated with intensive platinum-based chemotherapy regimens prior to stem cell transplant (SCT). This study was designed to learn the toxicity and efficacy of adding 4 doses of rituximab to the standard DHAP salvage chemotherapy regimen. Methods: Eligible pts had biopsy-proven relapsed CD20+ NHL and were eligible for platinum-based chemotherapy. Pts were treated with rituximab 375 mg/m2 d1,8,15, and 22 as well as cis-platinum 100 mg/m2 d3, cytosine arabinoside 2 g/m2 IV q 12 hours x two doses d4, dexamethasone 40 mg PO/IV d3–6, and G-CSF d5–14. Pts were restaged after 1 and 2 cycles; responding pts could proceed to SCT or further cycles of DHAP at MD discretion. There was no provision for rituximab maintenance. The goal was to achieve an overall response rate (ORR) of ≥ 75%. Results: Fifty-eight pts were enrolled between 10/29/00 and 6/20/03. The median age was 63 years (range, 43–83). One pt was ineligible because the tumor was CD20-. All 57 eligible pts completed one cycle; 48 pts completed 2 cycles. The ORR was 70% (40/57) with 16 (28%) CR/CRu and 24 (42%) PR. For all 57 pts, the median TTP was 13.1 months (mos) (95% CI: 7.3–18.2) and the median OS 30.5 mos (95% CI: 17.8–52.5). Seventeen pts (30%) proceeded to SCT. The median duration of response (DR), time to progression (TTP) and overall survival (OS) for the SCT pts were 41.6, 42.3, and 43.6 mos, respectively. The median DR, TTP, and OS for the 25 pts who responded to RDHAP but did not proceed to SCT were 12.4, 13.1, and 38.8 mos, respectively. The incidence of grade 3 and 4 thrombocytopenia was 53% and 39%, respectively. The incidence of grade 3 and 4 neutropenia was 11% and 68%, respectively. Six pts (11%) had nephrotoxicity–five grade 3 and two grade 4 (one pt had both) and one pt required dialysis. Conclusions: The addition of rituximab to standard DHAP is safe with similar toxicity profile to DHAP alone. Despite a high ORR, the CR rate and the % pts proceeding to SCT in this cooperative group setting remain low. New agents are needed that can be added to these regimens to increase the effectiveness and reduce toxicity to allow more pts to proceed to SCT. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. E. Witzig
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - S. M. Geyer
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - P. J. Kurtin
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - J. P. Colgan
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - D. J. Inwards
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - I. N. Micallef
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - J. C. Michalak
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - M. Salim
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - D. A. Nikcevich
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| | - T. R. Fitch
- Mayo Clinic, Rochester, MN; Siouxland Regional Cancer Center, Sioux City, IA; Allan Blair Cancer Center, Regina, SK, Canada; Duluth Clinic, Duluth, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
15
|
Inwards DJ, Hillman DW, Fishkin PA, White WL, Morton RF, Dakhil SR, Nikcevich DA, Wender DB, Fitch TR, Kurtin PJ. Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17505 Background: A previous trial of 2-CDA as a single agent for therapy of mantle cell lymphoma demonstrated this agent to be efficacious with an overall response rate of 81% (31% complete responses) (Blood 1999 Nov 15; 94:660a). A phase II study of the addition of rituximab to 2-CDA was conducted by the North Central Cancer Treatment Group based on improved outcomes achieved by the addition of rituximab to other regimens active in MCL. Methods: This one-stage phase II study was designed to determine the complete response (CR) or complete response/unconfirmed (CRu) rate. Central pathology confirmation of cyclin D1 positive mantle cell lymphoma was required. No previous therapy for lymphoma was allowed, with the exception of splenectomy. The shedule was rituximab 375 mg/m2 IV day 1; 2-CDA 5 mg/m2/d IV days 1–5 of a 4-week cycle. After 2 of the first 6 patients developed grade 4 neutropenia, subsequent patients received either pegfilgrastim or filgrastim support. Patients received 2–6 cycles of therapy, depending on response. Patients were required to achieve at least a PR after 2 cycles of therapy to continue on protocol therapy. Results: Patient characteristics of all 29 eligible pts: median age: 70 (range: 41–86); 21 male, 8 female; PS 0 (55.2%), PS 1 (41.4%), PS 2 (3.5%); stage II (6.9%), stage III (3.5%), stage IV (89.7%); prior splenectomy (20.7%). The only grade 4 adverse event occurring more than once was neutropenia (20.7%). One patient died of cerebral ischemia in the setting of pneumonia without neutropenia. Response has been determined in 26 pts with 50.0% (95% CI: 30.0–70.0%) achieving a CR, none of whom have relapsed to date. Three patients progressed early at 17, 45, and 46 days, two of whom have died, and a fourth relapsed day 222. 10 pts (34.0%) went on to receive further therapy off study, 5 in less than a PR after 2 cycles, 2 in PR after study therapy, and 1 who went off study for a rash. At last contact, 26 (89.7%) were alive (median follow-up 10.7 months; range: 1–28). Conclusions: Rituximab and cladribine were well tolerated for the treatment of MCL in a group including elderly patients. The response rate may have been underestimated due to the study design, which required at least a PR after 2 cycles to continue therapy. Despite this, 50% achieved a complete remission. [Table: see text]
Collapse
Affiliation(s)
- D. J. Inwards
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - D. W. Hillman
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - P. A. Fishkin
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - W. L. White
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - R. F. Morton
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - S. R. Dakhil
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - D. A. Nikcevich
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - D. B. Wender
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - T. R. Fitch
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| | - P. J. Kurtin
- Mayo Clinic College of Medicine, Rochester, MN; Illinois Oncology Research Association, Peoria, IL; Medical Oncology and Hematology Associates, Des Moines, IA; Witchita CCOP, Witchita, KS; Duluth Clinic, Duluth, MN; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
16
|
Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ, Nikcevich DA. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17:652-6. [PMID: 16497828 DOI: 10.1093/annonc/mdl005] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. We therefore undertook this phase II study to test this combination in a multi-institutional, first-line clinical trial. PATIENTS AND METHODS Forty-four eligible patients with histologic or cytologic confirmation of the above malignancy were recruited. The cohort had Eastern Cooperative Oncology Group performance scores of 0, 1 and 2 in 59%, 39% and 2% of patients, respectively. Median age was 57 years (range 32-77 years). Adequate organ function was a requirement for study entry. All patients were prescribed docetaxel 75 mg/m2 intravenously on day 1 and capecitabine 825 mg/m2 orally twice a day on days 1-14 of a 21-day cycle. RESULTS The tumor response rate was 39% [95% confidence interval (CI) 23% to 55%]. There were two complete responses and the rest were partial. Median survival was 9.4 months (95% CI 6.3-10.7 months) and median time-to-tumor progression was 4.2 months (95% CI 3.6-5.6 months). There was one treatment-related death from a myocardial infarction and dysrhythmia. Commonly occurring grade 3 adverse events included neutropenia (11 patients), infection (five patients), constipation (three patients), thrombosis (three patients), dyspnea (three patients) and hand-foot syndrome (three patients). In addition, 24/45 patients developed grade 4 neutropenia. CONCLUSIONS The regimen docetaxel and capecitabine shows activity in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. This regimen merits further study.
Collapse
Affiliation(s)
- K F Giordano
- Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2005; 17:29-34. [PMID: 16303863 DOI: 10.1093/annonc/mdj063] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
PURPOSE The synergic combination of oxaliplatin and capecitabine has demonstrated activity against various gastrointestinal cancers, including colon cancer. We therefore undertook this phase II study to test this first-line combination in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia. PATIENTS AND METHODS Forty-three patients with histologic or cytologic confirmation of the above malignancy were recruited. The cohort had Eastern Cooperative Oncology Group performance statuses of 0, 1 and 2 in 47%, 51%, and 2%, respectively. Median age was 61 years (range 32-80). All had adequate organ function. Initially, patients were prescribed 130 mg/m2 intravenously on day 1 and capecitabine 1000 mg/m2 orally twice a day, on days 1-14 of a 21-day cycle. Four treatment-related deaths in the first 24 patients led to a reduction in capecitabine to 850 mg/m2 orally twice a day, days 1-14, for the remainder of the cohort. RESULTS The tumor response rate was 35% [95% confidence intervals (CI) 23% to 50%]. All responses were partial; seven of 24 occurred before the capecitabine dose reduction, and eight of 19 after. Median time to tumor progression was 4 months (95% CI 3.1-4.6), and median survival 6.4 months (95% CI 4.6-10). To date, there have been 36 deaths. Four were treatment-related (one infection, two myocardial infarctions, one respiratory failure), and all occurred before the capecitabine dose reduction. Notable grade 4 events from the entire cohort included diarrhea (two patients), vomiting (three), dyspnea (one), thrombosis (two) and anorexia (two). Grade 3 events included nausea (12 patients), diarrhea (12), fatigue (10), abdominal pain (seven), vomiting (six), dyspnea (six), hypokalemia (six), dehydration (five), hypokalemia (five) and infection (four). CONCLUSIONS Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia. The lower dose (capecitabine 850 mg/m2 orally twice a day, days 1-14, and oxaliplatin 130 mg/m2 intravenously on day 1) yielded an acceptable toxicity profile and merits further study.
Collapse
Affiliation(s)
- A Jatoi
- Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Tschetter LK, Novotny PJ, Loprinzi CL. A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. P. Steensma
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - R. Molina
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - D. A. Nikcevich
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - P. L. Schaefer
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - K. M. Rowland
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - T. Dentchev
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - L. K. Tschetter
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - P. J. Novotny
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| |
Collapse
|
19
|
Wong GY, Michalak JC, Sloan JA, Mailliard JA, Nikcevich DA, Novotny PJ, Warner DO, Kutteh L, Dakhil SR, Loprinzi CL. A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: A North Central Cancer Treatment Group study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. Y. Wong
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - J. C. Michalak
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - J. A. Mailliard
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - D. A. Nikcevich
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - P. J. Novotny
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - D. O. Warner
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - L. Kutteh
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Sioux City CCOP, Sioux City, IA; Missouri Valley Cancer Consortium, Omaha, NE; Duluth CCOP, Duluth, MN; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Wichita CCOP, Wichita, KS
| |
Collapse
|
20
|
Schild SE, Stella PJ, Brooks BJ, Mandrekar S, Bonner JA, McGinnis WL, Nikcevich DA, Adjei AA, Jatoi A, Jett JR. The Results of combined modality therapy for limited stage small cell lung cancer (LD-SCLC) in the elderly. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. E. Schild
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - P. J. Stella
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - B. J. Brooks
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - S. Mandrekar
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - J. A. Bonner
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - W. L. McGinnis
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - D. A. Nikcevich
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - A. A. Adjei
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - A. Jatoi
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| | - J. R. Jett
- Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN
| |
Collapse
|
21
|
McGaughey DS, Nikcevich DA, Long GD, Vredenburgh JJ, Rizzieri D, Smith CA, Broadwater G, Loftis JS, McDonald C, Morris AK, Folz RF, Chao NF. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2002; 7:274-8. [PMID: 11400949 DOI: 10.1053/bbmt.2001.v7.pm11400949] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To evaluate the efficacy of inhaled fluticasone propionate (Flovent) as prophylaxis against delayed pulmonary toxicity syndrome (DPTS) and decline in pulmonary function in breast cancer patients undergoing high-dose chemotherapy with the conditioning regimen of cyclophosphamide, cisplatin, and carmustine (CPB) followed by autologous stem cell transplantation (ASCT). PATIENTS AND METHODS Sixty-three consecutive patients with multinode-positive or metastatic breast cancer undergoing high-dose chemotherapy with CPB and ASCT who were treated at the Duke University Adult Bone Marrow Transplant Program. All patients were started on inhaled fluticasone propionate, 880 microg every 12 hours, for 12 weeks from the start date of their CPB conditioning regimen. Pulmonary function tests (PFTs) with a single-breath diffusing capacity of carbon monoxide (DLCO) were performed pre-ASCT as well as approximately 6 and 12 weeks post-ASCT. DPTS was defined as follows: (1) development of a nonproductive cough and dyspnea with or without fever, plus a fall in DLCO to less than 60% predicted; or (2) decline in DLCO to less than 50% predicted with or without symptoms. RESULTS Pulmonary function tests were done on all patients pre-ASCT, on 56 of the 63 patients at a median of 44 days (range, 25 to 73 days) post-ASCT, and on 51 of the 63 patients at a median of 96 days (range, 50 to 190 days) post-ASCT. The PFTs showed an average of an 8% (+/-26%) and 21% (+/-22%) decline in DLCO. These declines compare favorably with our historical control group of 45 consecutive breast cancer patients undergoing ASCT with CPB as a conditioning regimen, who experienced average declines in DLCO of 29% (+/-18%) (P < .001) and 33% (+/-18%) (P < .001) at comparable time periods post-ASCT. Delayed pulmonary toxicity syndrome occurred in 35% of treated patients compared to 73% of the historical controls (P = .0003). No patients died of DPTS or pulmonary problems, and there were no fungal pneumonias. CONCLUSION Inhaled fluticasone propionate may decrease the incidence of DPTS in patients treated with CPB as a conditioning regimen for ASCT, as well as help to preserve pulmonary function as measured by DLCO. These results are worthy of further study in a randomized clinical trial.
Collapse
Affiliation(s)
- D S McGaughey
- Adult Bone Marrow and Stem Cell Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Nikcevich DA, Abramson MA. Image of the month. Choledochal cyst. Gastroenterology 1998; 114:238, 423. [PMID: 9453481 DOI: 10.1016/s0016-5085(98)70471-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- D A Nikcevich
- Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA
| | | |
Collapse
|
23
|
Nikcevich DA, Duffie GP, Young MR, Ellis NK, Kaufman GE, Wepsic HT. Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice. Cell Immunol 1987; 109:349-59. [PMID: 2959374 DOI: 10.1016/0008-8749(87)90318-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Systemic administration of a single dose (300 mg/kg) of cyclophosphamide (Cy) induced the appearance of a population of suppressor cells in the bone marrow and spleens of mice. Suppressor cells were assayed by their capacity to inhibit the concanavalin A (Con A) blastogenesis or the mixed-lymphocyte response of normal C57Bl/6 spleen cells. Cy-induced bone marrow (Cy-BM) suppressor cells were present as early as 4 days following Cy therapy and their activity gradually decreased over the next 2 weeks. Cy-induced splenic (Cy-Sp) suppressor cells were maximally present on Days 6 through 10 following Cy therapy. Studies were performed to characterize the suppressor cells of bone marrow obtained 4 days after Cy treatment and of normal bone marrow (N-BM). Some suppressor activity was present in normal bone marrow. N-BM suppressor cells resembled cells of the monocyte/macrophage lineage in that they were slightly adherent to Sephadex G-10, sensitive to L-leucine methyl ester (LME), and insensitive to treatment either with anti-T-cell antibody and complement or with anti-immunoglobulin antibody and complement. Their suppressive activity was abrogated by incubation with either indomethacin or catalase. Cy-BM suppressor cells were also resistant to treatment with anti-T-cell and anti-immunoglobulin antibody and complement but were not adherent to Sephadex G-10 and not sensitive to LME. Their suppressive activity was partially eliminated by indomethacin alone or in combination with catalase. We conclude that Cy chemotherapy induces the appearance of a population of immune suppressive cells and that these cells appear first in the bone marrow and subsequently in the spleen.
Collapse
Affiliation(s)
- D A Nikcevich
- Department of Research Services, Edward J. Hines, Jr., Veterans Administration Hospital, Hines, Illinois 60141
| | | | | | | | | | | |
Collapse
|
24
|
Ellis NK, Young MR, Nikcevich DA, Newby M, Plioplys R, Wepsic HT. Stimulation of prostaglandin-dependent macrophage suppressor cells by the subcutaneous injection of polyunsaturated fatty acids. Cell Immunol 1986; 102:251-60. [PMID: 2948662 DOI: 10.1016/0008-8749(86)90419-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Polyunsaturated fatty acids (PUFAs), in the form of pure linoleic, linolenic, or arachidonic acid, were injected subcutaneously into male C57Bl/6 mice daily for 10 days. Injection of 3.6 mg/day of PUFA resulted in up to a two- to threefold increase in spleen weight. Spleen cell response to mitogens was reduced by about 70%; mixed lymphocyte responses were reduced by about 90% when compared to normal values. In admixture experiments, spleen cells from PUFA treated mice suppressed the mitogen induced blastogenic response of control spleen cells by up to 90%. Fractionation of spleen cells from PUFA treated mice by G-10 adherence resulted in an enrichment of suppressive activity in the adherent cells. The suppressive effect of G-10 adherent cells was abolished by the addition of indomethacin as well as by depletion of macrophages by treatments with agents such as carbonyl iron and leucine methyl ester. These studies indicate that the administration of PUFA has marked immunosuppressive effects in mice. These effects may be related to increased prostaglandin production and appear to be mediated by a macrophage type cell.
Collapse
|
25
|
Nikcevich DA, Young MR, Ellis NK, Newby M, Wepsic HT. Stimulation of hematopoiesis in untreated and cyclophosphamide treated mice by the inhibition of prostaglandin synthesis. J Immunopharmacol 1986; 8:299-313. [PMID: 3760591 DOI: 10.3109/08923978609026491] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Indomethacin (IN) was administered to untreated or to cyclophosphamide (CY) treated C57B1/6 mice to study the roles of prostaglandins in regulating hematopoiesis. The following hematopoietic parameters were quantitated: peripheral blood leukocyte (PBL) count; total nucleated cells per spleen; total nucleated cells per femur; and spleen weight. Assays were performed in vitro to measure the number of colony forming units (CFU) present in the bone marrow and spleen. Untreated mice administered IN had a transient rise in their PBL count. These animals also developed splenomegaly and had an increased number of nucleated cells in their spleen. All CY treated mice had a marked decrease in PBL count, spleen cellularity, bone marrow cellularity, and spleen size during the first 5 days after CY treatment. These observations were followed by hematopoietic recovery over the next 10 days. Cyclophosphamide treated mice exhibited a more rapid hematopoietic recovery when treated with IN than without IN treatment. Analysis of the CFU capacity of bone marrow and spleen cells in soft agar showed a larger number of CFU in the bone marrow and spleen of IN treated mice or of CY/IN treated mice than in animals not receiving IN. These results indicate that prostaglandins are involved in the regulation of hematopoiesis in untreated mice and that prostaglandins may limit the hematopoietic recovery of CY treated mice.
Collapse
|
26
|
DeSilva MA, Wepsic HT, Mizushima Y, Nikcevich DA, Larson CH. Modification of in vitro and in vivo BCG cell wall-induced immunosuppression by treatment with chemotherapeutic agents or indomethacin. J Natl Cancer Inst 1985; 74:917-21. [PMID: 3157819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
The in vitro inhibition of spleen cell blastogenesis response and the in vivo enhancement of tumor growth are phenomena associated with BCG cell wall (BCGcw) immunization. What effect treatment with chemotherapeutic agents and the prostaglandin inhibitor indomethacin would have on the in vitro and in vivo responses to BCGcw immunization was evaluated. In vitro blastogenesis studies showed that chemotherapy pretreatment prior to immunization with BCGcw resulted in a restoration of the spleen cell blastogenesis response. In blastogenesis addback studies, where BCGcw-induced irradiated splenic suppressor cells were admixed with normal cells, less inhibition of blastogenesis occurred when spleen cells were obtained from rats that had received the combined treatment of chemotherapy and BCGcw immunization versus only BCGcw immunization. The cocultivation of spleen cells from BCGcw-immunized rats with indomethacin resulted in a 30-40% restoration of the blastogenesis response. In vivo studies showed that BCGcw-mediated enhancement of intramuscular tumor growth of the 3924a ACI rat tumor could be abrogated by either pretreatment with busulfan or mitomycin or by the feeding of indomethacin.
Collapse
|